Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study.
about
Methods for specifying the target difference in a randomised controlled trial: the Difference ELicitation in TriAls (DELTA) systematic reviewMycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group.A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung diseasePredictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials.Outcome Measures for Clinical Trials in Interstitial Lung Diseases.Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.Cyclophosphamide for connective tissue disease-associated interstitial lung disease.Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective.
P2860
Q26824003-CF34635E-1E08-4A0B-ABC3-D008AD57C0F0Q33434238-A1B2E81A-AC2F-45A0-B8E4-5F5F450E9954Q34027197-6AFB4C63-3A49-4058-8501-AA494F3BBBF9Q35242200-14F5A7A3-2104-4518-AC5E-293EF65E7E45Q35489187-62FDF918-1F36-44F7-B479-173EC8979BC0Q36477472-80168392-5F29-419E-8F80-B963074A434CQ36726418-ED0F5B1A-78C6-4A1F-86C7-EF923EFA45C8Q46255484-C5684B3C-F943-4314-871F-1C9ADDEAFF01Q46662148-82CAB032-AB0E-4B6B-8BA7-93211FF2A69DQ47216089-CF2D9431-1B71-4613-8928-DCB215136295Q50230077-A98763C8-717A-48A9-992E-4D6F416C1ACA
P2860
Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Minimally important difference ...... om the Scleroderma Lung Study.
@en
Minimally important difference ...... om the Scleroderma Lung Study.
@nl
type
label
Minimally important difference ...... om the Scleroderma Lung Study.
@en
Minimally important difference ...... om the Scleroderma Lung Study.
@nl
prefLabel
Minimally important difference ...... om the Scleroderma Lung Study.
@en
Minimally important difference ...... om the Scleroderma Lung Study.
@nl
P2093
P2860
P356
P1433
P1476
Minimally important difference ...... om the Scleroderma Lung Study.
@en
P2093
Chi-Hong Tseng
Daniel E Furst
Dinesh Khanna
Donald P Tashkin
Michael Roth
Philip J Clements
for Scleroderma Lung Study Investigators
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEP284
P577
2009-09-23T00:00:00Z